{"id":"rabbit-atg-sanofi-genzyme","safety":{"commonSideEffects":[{"rate":null,"effect":"Cytokine release syndrome (fever, chills, malaise)"},{"rate":null,"effect":"Leukopenia and thrombocytopenia"},{"rate":null,"effect":"Infection (opportunistic and bacterial)"},{"rate":null,"effect":"Serum sickness"},{"rate":null,"effect":"Thrombophlebitis at infusion site"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rabbit ATG is derived from immunizing rabbits with human T lymphocytes, producing polyclonal antibodies against multiple T-cell surface antigens. These antibodies bind to circulating and tissue-resident T cells, leading to their elimination through complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and opsonization. This profound T-cell depletion suppresses cell-mediated immunity and is used to prevent or treat rejection in transplantation and certain autoimmune conditions.","oneSentence":"Rabbit ATG is a polyclonal antithymocyte globulin that depletes T lymphocytes by binding to T-cell antigens and triggering immune-mediated destruction.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:03:39.854Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of acute rejection in renal transplantation"},{"name":"Treatment of acute rejection in renal and other solid organ transplants"},{"name":"Aplastic anemia (severe)"}]},"trialDetails":[{"nctId":"NCT02784561","phase":"PHASE4","title":"Study of Busulfan and FLAG Conditioning Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2016-07","conditions":"Leukemia","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Thymoglobuline"],"phase":"marketed","status":"active","brandName":"rabbit ATG（Sanofi/Genzyme）","genericName":"rabbit ATG（Sanofi/Genzyme）","companyName":"Chinese PLA General Hospital","companyId":"chinese-pla-general-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rabbit ATG is a polyclonal antithymocyte globulin that depletes T lymphocytes by binding to T-cell antigens and triggering immune-mediated destruction. Used for Prevention of acute rejection in renal transplantation, Treatment of acute rejection in renal and other solid organ transplants, Aplastic anemia (severe).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}